HC Wainwright Reiterates Buy Rating for NextCure (NASDAQ:NXTC)

NextCure (NASDAQ:NXTC)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $3.00 price objective on the stock, down from their previous price objective of $4.00. HC Wainwright’s price target would suggest a potential upside of 300.00% from the stock’s previous close. HC Wainwright also issued estimates for NextCure’s FY2029 earnings at ($0.55) EPS.

NextCure Stock Up 5.2 %

Shares of NASDAQ NXTC opened at $0.75 on Friday. The stock’s fifty day simple moving average is $0.78 and its 200 day simple moving average is $1.12. The stock has a market capitalization of $21.01 million, a price-to-earnings ratio of -0.36 and a beta of 0.71. NextCure has a 52-week low of $0.66 and a 52-week high of $2.57.

NextCure (NASDAQ:NXTC) last issued its quarterly earnings results on Thursday, March 6th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). As a group, analysts anticipate that NextCure will post -1.87 earnings per share for the current year.

Institutional Investors Weigh In On NextCure

A number of large investors have recently made changes to their positions in the company. Citadel Advisors LLC grew its position in NextCure by 40.6% during the 4th quarter. Citadel Advisors LLC now owns 78,678 shares of the company’s stock worth $61,000 after purchasing an additional 22,724 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of NextCure by 14.2% in the third quarter. Geode Capital Management LLC now owns 223,741 shares of the company’s stock worth $307,000 after buying an additional 27,812 shares during the period. Peapod Lane Capital LLC acquired a new stake in shares of NextCure in the fourth quarter worth $311,000. Renaissance Technologies LLC grew its holdings in shares of NextCure by 27.9% during the fourth quarter. Renaissance Technologies LLC now owns 519,300 shares of the company’s stock valued at $400,000 after buying an additional 113,300 shares in the last quarter. Finally, Tang Capital Management LLC raised its position in NextCure by 7.3% during the fourth quarter. Tang Capital Management LLC now owns 700,000 shares of the company’s stock valued at $540,000 after buying an additional 47,614 shares during the period. Institutional investors and hedge funds own 42.65% of the company’s stock.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.